The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.

Celsius, a US-based cancer and autoimmune disease drug developer, has pocketed $83m in a funding round led by Casdin Capital and backed by founding investor Third Rock Ventures. The round included technology group Alphabet’s GV unit, medical care provider Heritage Provider Network and pharmaceutical firm Amgen’s corporate venturing arm Amgen Ventures. Life sciences-focused real estate investment trust Alexandria Real Estate Equities took part through Alexandria Venture Investments, while Amplitude Ventures, Catalio Capital, Co-Win Ventures, Fast Track Initiative, Section 32 and unnamed institutional investors also took part. Celsius was launched by Third Rock Ventures to commercialise research originating at University of California (UC), San Francisco, Harvard University, Johns Hopkins University and Broad Institute of Massachusetts Institute of Technology and Harvard University. Celsius previously raised $65m in series A financing in 2018.

EneCoat, a Japan-based perovskite solar cell developer, has raised ¥1.59bn ($12.9m) in a series B round backed by Kyoto…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).